Biocon Biologics Ltd Introduces the Biosimilar HULIO in the United States

After five years in Europe and two years in Canada, Biocon Biologics Ltd announced that HULIO injection, a biosimilar to Humira, is now available to patients in the United States. HULIO meets the FDA's stringent biosimilar approval standards. HULIO, like Humira, is free of citrates and is made without natural rubber latex. HULIO360 is a robust patient support programme offered by Biocon Biologics that includes benefits verification and prior authorization support, copay assistance, a bridge programme for eligible patients, and at-home nurse injection training.

"The launch of HULIO, our biosimilar adalimumab, in the United States is an important milestone for Biocon Biologics because it expands our well-known biosimilar product offering to patients in the United States," Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd. said. "Biocon Biologics is pleased to make HULIO, a patient-friendly, 2-click, prefilled pen for patients with certain inflammatory diseases, available in the United States." There are no controls to operate. To start their injection, patients remove the cap and press the device against their skin. "With HULIO, healthcare professionals and patients don't have to miss a beat; simply 'Click, Click, Go,'" said Mathew Erick, Chief Commercial Officer, Advanced Markets, Biocon Biologics Ltd.